News | July 18, 2022
China Pharma submits plan of compliance to NYSE American
The company was directed to submit a plan of compliance by July 15, 2022
The company was directed to submit a plan of compliance by July 15, 2022
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Subscribe To Our Newsletter & Stay Updated
